2022

IMC-F106C Shows Potential as T-cell Receptor–Driven Therapy in Melanoma

Results from a first-in-humanphase 1 trial (NCT04262466) evaluating the efficacy and safety of IMC-F106C in patients with PRAME-positive metastatic/unresectable tumors showed a significant clinical benefit with the first PRAME×CD3 ImmTAC therapy, and could specifically fulfill unmet needs for patients with melanoma, according to Omid Hamid, MD.

Read More
MRV News
Melanoma News
Archive
Menu